A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC. (TRI-611-101)
Clinical Trial Grant
Awarded By
TRIANA Biomedicines, Inc.
Start Date
June 26, 2026
End Date
June 21, 2031
Awarded By
TRIANA Biomedicines, Inc.
Start Date
June 26, 2026
End Date
June 21, 2031